{"name": "Savient Pharmaceuticals",
 "permalink": "savient-pharmaceuticals",
 "crunchbase_url": "http://www.crunchbase.com/company/savient-pharmaceuticals",
 "homepage_url": "http://www.savientpharma.com",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "",
 "phone_number": "732-418-9300",
 "description": "",
 "created_at": "Wed Jan 26 07:45:38 UTC 2011",
 "updated_at": "Wed Jan 26 07:51:21 UTC 2011",
 "overview": "\u003Cp\u003ESavient Pharmaceuticals is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA\u00e2\u201e\u00a2 (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University (\u0026#8220;Duke\u0026#8221;) and Mountain View Pharmaceuticals, Inc. (\u0026#8220;MVP\u0026#8221;).  Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA.  Savient also manufactures and supplies Oxandrin\u00c2\u00ae (oxandrolone tablets, USP) CIII in the U.S.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       44],
      "assets/images/resized/0011/9049/119049v1-max-150x150.jpg"],
     [[250,
       74],
      "assets/images/resized/0011/9049/119049v1-max-250x250.jpg"],
     [[287,
       86],
      "assets/images/resized/0011/9049/119049v1-max-450x450.jpg"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "Chief Executive Officer",
    "person":
     {"first_name": "John",
      "last_name": "H. Johnson",
      "permalink": "john-h-johnson",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$0",
 "funding_rounds":
  [],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "One Tower Center",
    "address2": "Fourteenth Floor",
    "zip_code": "08816",
    "city": "East Brunswick",
    "state_code": "NJ",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [{"available_sizes":
     [[[150,
        145],
       "assets/images/resized/0011/9050/119050v1-max-150x150.jpg"],
      [[250,
        241],
       "assets/images/resized/0011/9050/119050v1-max-250x250.jpg"],
      [[450,
        435],
       "assets/images/resized/0011/9050/119050v1-max-450x450.jpg"]],
    "attribution": null}],
 "external_links":
  []}